Anti-p14 ARF (P16) AntibodyDatasheet
|Description:||Rabbit polyclonal antibody to p14 ARF (P16) .|
|Applications:||WB, IHC, IF|
|Immunogen:||A synthetic peptide of human CDKN2A|
|Formulation:||PBS with 0.02% sodium azide, 50% glycerol, pH7.3.|
|Synonyms:||CDKN2A; ARF; CDK4I; CDKN2; CMM2; INK4; INK4a; MLM; MTS1; TP16; p14; p14ARF; p16; p16INK4; p16INK4a; p19; ARF; CDKN2A|
|Background:||The division cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (CDKs). The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle. It has been reported that CDKN2A binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzymes. CDKN2A seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retinoblastoma protein (1). The INK4 (inhibitor of cyclin-dependent kinase 4) family consists of four tumor-suppressor proteins: p15(INK4B), CDKN2A(INK4A), p18(INK4C), and p19(INK4D). While their sequences and structures are highly homologous, they show appreciable differences in conformational flexibility, stability, and aggregation tendency (2). Cell cycle arrest at the G1 checkpoint allows completion of critical macromolecular events prior to S phase. Regulators of the G1 checkpoint include an inhibitor of cyclin-dependent kinase, CDKN2AINK4; two tumor-suppressor proteins, p53 and RB and cyclin D1. CDKN2AINK4 is a tumor-suppressor protein and that genetic and epigenetic abnormalities in genes controlling the G1 checkpoint can lead to both escape from senescence and cancer formation (3).|
|Storage:||Store at -20℃. Avoid freeze / thaw cycles.|
|Recommended Dilutions:||WB 1:500 - 1:2000, IHC 1:50 - 1:200, IF 1:50 - 1:200|
Target (Information from UniProt)
|Function:||Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.|
|Tissue Specificity:||Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.|
|Involvement in Disease:||Melanoma, cutaneous malignant 2: A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome: An inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer.
Melanoma-astrocytoma syndrome: Characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.
|Sequence Similarities:||Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.|
|Post-Translational Modification:||Phosphorylation seems to increase interaction with CDK4.|
|Cellular Location:||Cytoplasm. Nucleus.|
Western blot analysis of extracts of various cell lines, using CDKN2A antibody.
Immunofluorescence analysis of A549 cells using CDKN2A antibody.